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Abstract 
Poly(acrylamide-co-acrylonitrile) (P(AAm-co-AN)), an upper critical solution temperature (UCST)-
type copolymer in water, was synthesized by reversible addition fragmentation chain transfer 
(RAFT) copolymerization and used as a macro-RAFT agent for the polymerization of oligo(ethylene 
glycol) methyl ether methacrylate (OEGMA) to yield amphiphilic diblock P(AAm-co-AN)-b-POEGMA 
copolymer. A series of copolymers with different AN content was obtained allowing to finely tune 
the UCST behavior (cloud point (Tt-UCST) from 35 to 78°C). Addition of the POEGMA block did not 
modify the Tt-UCST regardless its Mn but provided a lower critical solution temperature behavior at 
high temperature. Nanoparticles were then formulated by the nanoprecipitation technique 
revealing that copolymers with higher Tt-UCST yield smaller, better-defined nanoparticles. Eventually, 
doxorubicin (Dox) was encapsulated into nanoparticles made from the copolymer having a Tt-UCST 
close to mild hyperthermia (~43°C). Surprisingly, Dox encapsulation increased Tt-UCST and gave 
smaller nanoparticles as opposed to their unloaded counterparts. The dilution of the suspension 
also led to a decrease of Tt-UCST. No obvious hyperthermia effect was observed on the cytotoxicity 
of Dox-loaded nanoparticles. Our study highlighted the influence of macromolecular engineering, 
drug encapsulation and nanoparticle dilution on UCST behavior, important features often 
overlooked despite their crucial impact in the development of thermosensitive nanoscale drug 
delivery systems. 
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1. Introduction 
Nanomedicine holds great promise in dealing with the shortcomings of fragile and/or poorly 
soluble anticancer drug formulations, such as longer circulation time[1] and fewer side effects for 
the healthy tissues.[2] Newer generations of nanoparticles aim at going one step further by 
allowing full control of the spatial and temporal release of the drug. This is made possible by, for 
instance, employing stimulus-responsive starting material to build the drug carrier.[3] 
Temperature is an easy-to-use trigger that can be exploited through mild hyperthermia, 
corresponding to an elevation of tissue temperature from 37 °C to 43 °C.[4] Clinicians dispose of a 
wide array of tools to locally heat tissue, such as ultrasound,[5] microwave,[6] radiofrequency[7] 
and infrared[8] energy sources. Mild hyperthermia has a biological effect on the tumor 
microenvironment as the endothelial tissue becomes more permeable[9,10] and immune response 
is enhanced.[11,12] Thus, the prospect of using mild-hyperthermia with tailored nanomedicine is 
enthralling and should lead to better disease management.[13] To the best of our knowledge, only 
one thermoresponsive formulation of doxorubicin (Dox) exists in clinical stages of development. It 
is in the form of thermosensitive liposomes that are currently undergoing phase 3 of clinical trials, 
under the name of ThermoDox® by Celsion.[14] ThermoDox® is intended to work as a companion 
for radiofrequency tumor ablation. It is administered intravenously while the tumor is being 
ablated by radiofrequency. The generated heat triggers the local release of Dox that in turn exerts 
its effect on the remaining tumor cells that were not fully ablated by radiofrequency. Although the 
formulation is in clinical trials, there are still some limitations regarding this system as liposomes 
are fragile and have poor drug retention.[15,16]  
In contrast, polymer nanoparticles may provide better drug retention and in terms of polymer 
chemistry, there is still no thermoresponsive polymer nanoparticle formulation undergoing clinical 
trials. Lower critical solution temperature (LCST) thermoreponsive polymers have been used to 
produce thermoresponsive nanocarriers for several decades,[17] but yet without successful 
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translation to the clinic.[18] These polymers are soluble in water below the LCST and insoluble 
above. On the other hand, upper critical solution temperature (UCST) polymers are less widely 
investigated while their thermoresponsiveness appears more intuitive as they are fully soluble 
above the UCST and insoluble below. An example of such polymer is poly(acrylamide-co-
acrylonitrile) (P(AAm-co-AN)),[19] a UCST-type copolymer that owes its thermoresponsiveness to 
the reversible hydrogen bonds made between the copolymer chains below the UCST and the 
surrounding water molecules above the UCST. In terms of polymer synthesis, P(AAm-co-AN) can be 
easily synthesized by free-radical polymerization[19–21] or reversible deactivation radical 
polymerization techniques such as reversible addition fragmentation chain transfer (RAFT) 
polymerization.[22–26] The copolymer obtained by free-radical polymerization has been grafted 
with poly(ethylene glycol) (PEG) on the acrylamide monomers to formulate thermoresponsive 
nanoparticles efficiently responding to mild-hyperthermia for in vivo tumor treatment.[27]  
Here, we design a different synthetic route to yield a well-defined, amphiphilic block copolymer. A 
poly(acrylamide-co-acrylonitrile)-b-poly[(oligo(ethylene glycol) methyl ether methacrylate)] 
(P(AAm-co-AN)-b-POEGMA) diblock copolymer was synthesized by RAFT polymerization of 
OEGMA from a P(AAm-co-AN) UCST-type macro-RAFT agent. This strategy allowed control on the 
size of both the thermoresponsive block and the hydrophilic block. Copolymers with different Mn 
and AN content were synthesized to optimize the cloud point (Tt-UCST) for mild hyperthermia. These 
copolymers were then formulated into nanoparticles and the influence of the Tt-UCST on the physico-
chemical properties of the colloidal suspension was investigated. We also evaluated the effect of 
Dox encapsulation on nanoparticle thermoresponsiveness and characteristics, as the influence of 
drug encapsulation is often overlooked despite its crucial impact in the development of 
thermosensitive nanoscale drug delivery systems. Finally, Dox-loaded nanoparticle cytotoxicity was 
assessed in vitro on ovarian cancer cells with or without application of hyperthermia.  
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2. Materials and methods 
2.1. Materials 
Acrylamide (AAm) (Sigma-Aldrich) was recrystallized in chloroform, acrylonitrile (AN) (Sigma-
Aldrich) was purified by passing through a column filled with activated, basic, Brockman I 
aluminum oxide. Azobisisobutyronitrile (Sigma-Aldrich) was recrystallized in ethanol. 
Oligo(ethylene glycol) methyl ether methacrylate (OEGMA) (Mn ~ 300 g.mol-1, Sigma-Aldrich), 2-
cyano-2-propyl benzodithioate (CPDB) (Sigma-Aldrich), doxorubicin hydrochloride (Dox.HCl) 
(Carbosynth), and triethylamine (TEA) (Sigma-Aldrich) were used as received. RPMI-1640 cell 
culture medium and bovine insulin were purchased from Sigma-Aldrich. Water was purified using a 
MilliQ Reference system from Merck-Millipore. Solvents were of HPLC analytical grade and were 
provided by Carlo Erba (Italy). For NMR measurements, d6-DMSO was provided by Eurisotop 
(France). 
2.2. Fourier transform infrared (FTIR) spectroscopy for AN quantification 
KBr pellets containing the polymer samples were prepared for transmission FTIR analysis using 
FTIR Spectrum One (PerkinElmer) by mixing polymer samples with KBr at 5 wt.% and running 5 
scans at 4 cm-1 resolution per sample. For mol.% AN determination, a calibration curve was 
obtained by mixing PAAm and PAN (both from Sigma-Aldrich) at determined ratios and by 
calculating the peak area ratio between the carbonyl peak (C=O at 1659 cm-1) and the nitrile peak 
(C≡N at 2242 cm-1) (Supplementary Information, Fig. S7). Experiments were performed in  
2.3. Nuclear magnetic resonance (NMR) spectroscopy 
1H NMR spectroscopy was performed in 5 mm diameter tubes in d6-DMSO at 70 °C for 128 scans on 
a Bruker Avance 3 HD 400 spectrometer at 400 MHz. NMR determination of the Mn of P(AAm-co-
AN) copolymers was achieved by integrating the triplet between 7.88 and 7.98 ppm corresponding 
to 2 aromatic protons from the CPDB end-chain (noted a in Supplementary Information, Fig. S1) 
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and the broad peak between 1.40 and 2.09 ppm assigned to the protons of the methylene group in 
all monomer units (noted g in Supplementary Information, Fig. S1), that allowed determination of 
the total content in AAm and AN. By using the measured mol.% AN using method 2.2., the Mn was 
then determined. For P(AAm-co-AN)-b-POEGMA copolymers, integration of the broad peak 
between 6.25 and 7.75 ppm corresponding to the NH2 protons of the acrylamide, was compared to 
the integration of the peak between 3.95 and 4.18 ppm corresponding to 2 OEGMA protons 
(Supplementary Information, Fig. S1). 
2.4. Size exclusion chromatography (SEC) 
SEC was performed at 50 °C with two columns from PSS Gram (GPC column 300 x 8 mm; bead 
diameter 10 µm; molar mass range 500 - 106 g.mol-1) and a triple detection system (Viscotek 
TDA/GPCmax from Malvern) with a differential refractive index detector, low and right-angle light 
scattering detectors and a differential viscometer detector. The eluent was dimethyl sulfoxide 
(DMSO) at a flow rate of 0.7 mL.min-1. The system was calibrated using a narrow pullulan standard 
and each polymer sample was injected at 5 different injection volumes for the determination of the 
dn/dc parameter. This allowed the determination of the number-average molar mass (Mn), the 
weight-average molar mass (Mw) and the dispersity (Ð = Mw/Mn).  
2.5. Suspension turbidity for Tt-UCST and Tt-LCST determination 
Light transmittance (%) of samples was measured using a Lambda 25 UV/VIS spectrometer 
equipped with a PTP 1+1 Peltier system for temperature control (PerkinElmer). Samples were 
prepared at 4.5 mg.mL-1, spectrometer wavelength was set at 600 nm, temperature ramp was at 0.5 
°C.min-1 and data acquisition was performed every 30 s. The transition temperature Tt-UCST is 
defined as the point at which the transmittance reaches a maximum plateau for UCST behavior. For 
LCST behavior Tt-LCST corresponds to the point at which the transmittance reaches a minimum 
plateau. 
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2.6. Dynamic light scattering (DLS) and zeta potential 
Nanoparticle intensity-averaged diameters (Dz) and zeta potentials (ζ) were measured by dynamic 
light scattering (DLS) with a Nano ZS from Malvern (173° scattering angle) at a temperature of 20 
°C. The surface charge of the nanoparticles was investigated by ζ-potential (mV) measurement at 20 
°C after dilution with 1 mM NaCl, using the Smoluchowski equation. Experiments were performed 
in triplicate. 
2.7.  UV spectroscopy for doxorubicin quantification 
3 mL of the suspension were centrifuged at 20,000 g for 1 h at 4 °C (Optima LE-80K Ultracentrifuge 
Beckman Coulter). The supernatant was discarded, and the pellet was dissolved in 5 mL of DMSO. 
The dissolved samples were put in 96-well plates before quantification at 490 nm by a plate reader. 
Calibration curve was determined by preparing a solution of Dox at 6 mgmL-1 and TEA (35 µL) in 
DMSO and subsequent dilution to a range between 6 and 200 µg.mL-1 of Dox. Drug loading (DL, 
wt.%) and encapsulation efficiency (EE, wt.%) were calculated using the following formulas: 
DL = 
                       
                                       
     
EE = 
                       
                  
     
Experiments were performed in triplicate. 
 
2.8. Transmission electron microscopy (TEM) 
TEM images were obtained using transmission electron microscope of 80 kV Jeol 1400 (Imagif, 
I2BC, CNRS, Gif-sur-Yvette, France). Briefly, each suspension was diluted ten-fold in water. Then, 3 
μL of this dilution were placed on a glow-discharged copper grid covered with formvar-carbon film. 
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The excess solution was blotted off using a filter paper. Images were acquired using an Orius 
camera (Gatan Inc, USA). 
 
2.9. Synthesis of P(AAm-co-AN)  
The overall procedure was adapted from the work of Zhang et al.[22] Proportions were changed 
according to the desired polymer composition. A typical synthesis (T2) is as follows: AIBN (2.3 mg, 
0.014 mmol), CPDB (15.7 mg, 0.071 mmol), AAm (3.324 g, 46.76 mmol), AN (0.918 g, 17.29 mmol) 
and DMSO (16.01 mL) were charged in a 50 mL-round-bottom flask. For other copolymer 
compositions, see details in Supplementary Information (Table S2). The mixture was purged with 
argon for 15 min under vigorous stirring before being placed in a 70 °C-oil bath for 24 h under 
stirring. After the reaction, the copolymer was precipitated twice in methanol (20 times the volume 
of the mixture). The copolymer was further solubilized in DMSO and placed in a 3.5 kD Spectra/Por 
3 dialysis bag for dialysis against water for 3 days at room temperature (20°C), with dialysis water 
changed twice per day. The dialysate was then freeze-dried to yield P(AAm-co-AN) as a red hard 
solid paste.  
2.10. Synthesis of P(AAm-co-AN)-b-POEGMA 
P(AAm-co-AN) was used as a macro-RAFT agent to polymerize OEGMA and yield a P(AAm-co-AN)-
b-POEGMA diblock copolymer.  An example of synthesis as follows: P(AAm-co-AN) (T2) (200 mg, 
6.25 µmol), OEGMA (75 mg, 250 µmol), AIBN (1.7 mg, 10.4 µmol) and DMSO (4.5 mL) were charged 
in a 20 mL-vial. The mixture was purged with argon for 15 min under vigorous stirring before being 
placed in a 70 °C-oil bath for 5 h under stirring. The mixture was directly put into a 3.5 kD 
Spectra/Por 3 dialysis bag for dialysis against water for 24 h, with dialysis water changed three 
times. The dialysate was then freeze-dried to yield the diblock copolymer as a white-reddish soft 
solid paste. 
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2.11. Unloaded nanoparticle formulation 
Preparation of thermoresponsive copolymer nanoparticles was carried out using the 
nanoprecipitation technique. 50 mg of copolymer were dissolved in 1 mL of DMSO. The solution 
was added at 150 µL/min using a syringe pump (Harvard Apparatus Pump 11 Pico Plus Elite) to 10 
mL of water (or PBS 10mM) under vigorous stirring. To remove DMSO, the suspension was put into 
a 3.5 kD Spectra/Por 3 dialysis bag for dialysis against water (or PBS) for 24 h, with dialysis 
medium changed twice.  
2.12. Doxorubicin-loaded nanoparticle formulation 
The protocol was adapted from Huang et al.[23] and is described as follows: 50 mg of copolymer 
were dissolved in 500 µL of DMSO. Dox.HCl (5 mg, 8.62 µmol) was dissolved in 500 µL of DMSO 
prior to addition of 35 µL (251 µmol) of TEA and the solution was stirred for 7 h shaded from light 
at room temperature. The copolymer and Dox solutions were then mixed, and the following steps 
were the same as in 2.11. in water only, with the solutions shaded from light. For the drug 
encapsulation curve, the amount of initial Dox.HCl varied from 1 to 5 mg. 
2.13. Cell culture 
Nanoparticle cytotoxicity was evaluated on the human ovarian carcinoma cell line OVCAR-3 
obtained from ATCC (USA). OVCAR-3 cells were cultured in RPMI-1640 medium supplemented with 
100 U/mL penicillin, 20% heat inactivated FBS, and 0.01 mg.mL-1 bovine insulin. The cell line was 
maintained at 37 °C and 5% CO2 in a humidified atmosphere and cells were split twice weekly. The 
cell viability was evaluated using the 3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyltetrazolium bromide 
(MTT) assay. Briefly, cells were seeded in 100 μL of culture medium (8 x 103 cells/well for 72 h 
incubation) in 96 well plates (TPP, Switzerland) and pre-incubated for 24 h. 100 μL of a serial 
dilution of nanoparticle suspension was then added to the medium. After 72 h of incubation, 20 μL 
of MTT solution (5 mg.mL-1 in PBS) was added to each well. After 4 h incubation, the culture 
10 
 
medium was gently aspirated and replaced by 200 μL DMSO (ACS grade, VWR, France) to dissolve 
the formazan crystals. The absorbance of the solubilized dye, which correlates with the number of 
living cells, was measured with a microplate reader (LAB Systems Original Multiscan MS, Finland) 
at 570 nm. The percentage of viable cells in each well was calculated as the absorbance ratio 
between nanoparticle-treated and untreated control cells. For hyperthermia studies, the protocol 
was the same except cells were incubated at 43 °C for 30 min, either 6 h or 24 h after nanoparticle 
addition to the wells. After 30 min, the cells were put back in the incubator at 37 °C until they had 
been exposed for a total of 72 h. Experiments were performed in triplicate. Data was fitted to a Hill 
slope model with four parameters using GraphPad Prism 7 which allowed determination of the IC50 
for the Dox-containing treatments. The different IC50 values were compared using a one-way 
ANOVA test with GraphPad Prism 7. 
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3. Results and discussion 
3.1. Thermoresponsive copolymer synthesis and UCST behavior 
Thermoresponsive poly(acrylamide-co-acrylonitrile) (P(AAm-co-AN)) copolymers with different 
AN contents were synthesized to evaluate the dependency of the UCST behavior relative to the AN 
content (Fig. 1, T1–T8, Table 1). Among the different reversible deactivation radical polymerization 
techniques, RAFT polymerization was chosen for its simplicity, its ability to control such monomers, 
together with its capability to form well-defined block copolymers by efficient chain-extension from 
macro-RAFT agents (Fig. 1).[28–31] AN content was determined by infrared spectroscopy against a 
pre-determined calibration curve (Supporting Information, Fig. S7). AN content was in good 
correlation with the theoretical value, yet the technique was not completely robust as values for T4 
and T8 had an important standard deviation and it proved difficult to get a good measurement for 
T3. After synthesis of the P(AAm-co-AN) block, our approach consisted in performing its chain-
extension by polymerizing oligo(ethylene glycol) methyl ether methacrylate (OEGMA, Mn ~300 
g.mol-1) under RAFT control to yield the corresponding P(AAm-co-AN)-b-POEGMA diblock 
copolymer comprising a thermoresponsive UCST-type block and a hydrophilic one (Fig. 1, P1 – P8, 
Table 2). Importantly, the hydrophilic POEGMA block acts as a biocompatible and protein repellent 
corona to prolong the blood circulation time of the nanoparticles (the so-called “stealth” 
feature).[32,33] The Mn of the different copolymers was measured both by 1H-NMR and a triple 
detection SEC (that allows absolute Mn values to be determined). Even though SEC is the most used 
method for Mn determination, 1H-NMR is appealing as integration of chain-end protons allows 
precise Mn measurement (irrespectively of the nature of the polymer), providing the Mn is rather 
low. In our case, since we have synthesized relatively large copolymers (Mn,SEC =20–63 kg.mol-1), 
some discrepancies were observed between, Mn,SEC and Mn,NMR (Fig. 1, Table 1 and 2). Overall, well-
defined copolymers were obtained with dispersity values below 1.2 for both the thermoresponsive 
block and the diblock copolymers. Copolymers P1 to P7 were soluble in DMSO or in hot water 
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(above their Tt, up to 80 °C), whereas P8 was only soluble in DMSO. These results indicate that ~40 
mol.% AN is too high for hyperthermia as it yielded a water-insoluble copolymer with an out-of- 
range UCST value (> 100 °C).  
 
 
 
Figure 1: Synthesis of a series of UCST thermoresponsive poly(acrylamide-co-acrylonitrile), 
P(AAm-co-AN), copolymers (T1 – T8, Table 1) used as macro-RAFT agents to yield 
poly(acrylamide-co-acrylonitrile)-b-poly[(oligo(ethylene glycol) methyl ether methacrylate)] 
(P(AAm-co-AN)-b-POEGMA) diblock copolymers (P1 – P8, Table 2). Table 1: AN content 
determined by IR spectroscopy, value given with SD. Mn-NMR calculated by 1H NMR in d6-DMSO. *: 
sample was difficult to process into KBr pellets and measured value was out of calibration range. 
ins.: insoluble in water at any temperature. Table 2: Mn-NMR calculated by 1H NMR in d6-DMSO. Mn-SEC 
determined by triple detection SEC in DMSO. Ð is polymer dispersity. Tt determined by UV-vis 
temperature ramp at 4.5 mg.mL-1 in PBS. ins. : insoluble in water at any temperature. SEC 
chromatograms of P1-P8 are presented in Supplementary Information (Fig. S3). 
 
The influence of PEGylation on the thermoresponsiveness of the P(AAm-co-AN) block was then 
investigated. Addition of the POEGMA block had no impact on the Tt-UCST, as shown with T3 and P3a 
– P3c (Fig. 2a) until a certain chain length where POEGMA exhibited a LCST[34] behavior that was 
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influenced by its Mn (Fig. 2b). Despite the increasing Mn of the hydrophilic POEGMA blocks added to 
T3, from 4,900 g.mol-1 to 22,400 g.mol-1, it did not prevent the diblock copolymers to retain their 
thermoresponsiveness. This is true even for P7, having a Mn composed 50% by the 
thermoresponsive block and 50% by the hydrophilic block, which retained its UCST properties. 
Importantly, the Tt-LCST values of T3-based thermosensitive diblock copolymers were all ≥ 70 °C, 
which is much higher than mild-hyperthermia (43 °C) and should not hamper the mild-
hyperthermia-mediated drug release.  
 
 
Figure 2: (a) Thermoresponsive properties (transmittance curves, 4.5 mg.mL-1 in water) of P(AAm-
co-AN) T3 and P(AAm-co-AN)-b-POEGMA diblock copolymers of different Mn P3a to P3c. (b) Tt-UCST 
and Tt-LCST values of the synthesized copolymers. Mn was calculated by 1H-NMR, Tt-LCST is the 
temperature at which the transmittance reaches a minimum plateau, n.m. : not measurable. SEC 
chromatograms are presented in Supplementary Information (Fig. S3). 
 
Since these copolymers are intended for use in a biological setting, we have evaluated the influence 
of the presence of electrolytes on their UCST behavior in water and in PBS. For P2, we observed 
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that the copolymer in water did not exhibit a marked hysteresis and the heating and cooling Tt-UCST 
were nearly identical (Supplementary Information Fig. S4a). The effect of ionic strength and pH was 
then assessed by measuring the Tt-UCST in PBS. The hysteresis is here more pronounced compared to 
that obtained in water (Supplementary Information Fig. S4b). When comparing the heating and 
cooling curves in water and PBS, Tt-UCST remained constant at 47 °C in both media, but the 
thermoresponsiveness onset for the heating curve occurred earlier in PBS (30 °C) than in water (35 
°C) (Supplementary Information Fig S4c and S4d). The slightly different behavior between PBS and 
water might be due to a change in the hydration state of the copolymer chains. With higher ionic 
strength, the copolymer is more readily solubilized. Nevertheless, since the thermoresponsiveness 
of the copolymer relies on reversible hydrogen bonds between the different copolymer chains, this 
property is maintained even at higher ionic strength, which represents a strong advantage for use 
in a biological context as compared with charged or zwitterionic UCST-type (co)polymers.[35]  
The influence of the AN content on thermoresponsiveness was then assessed directly on the 
P(AAm-co-AN)-b-POEGMA diblock copolymers (P1 to P8). The Tt-UCST of the copolymers increased 
with increasing AN content (Fig. 3a and 3b). The trend was not clearly defined due to the IR 
measurements of the AN content in the polymers being not precise enough. For 40 mol.% AN (P8), 
the copolymer was insoluble in water at any temperature. While the copolymers had different Mn 
values ranging between 25 and 82 kg.mol-1, this parameter did not appear to have as much impact 
as the AN content. 
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Figure 3: Heating transmittance curves of the different polymers at 4.5 mg.mL-1 in PBS (a) and Tt-
UCST plotted against the measured AN mol.% content (b). Intensity-averaged diameter (Dz) and 
polydispersity index (PdI) in water measured by DLS of P(AAm-co-AN)-b-POEGMA diblock 
copolymers nanoparticles as a function of the Tt-UCST (c). The tags on each data point correspond to 
the polydispersity index (PdI). The line at 154 nm represents the Dz of nanoparticles obtained with 
the non-thermoresponsive polymer P8 (PdI = 0.05). For each sample n ≥ 3.  
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3.2. Nanoparticle formulation 
As the different copolymers were only soluble in DMSO, which is a water-miscible solvent, the 
nanoparticles were thus prepared by the nanoprecipitation technique.[36] The average diameters 
and polydispersity indexes of the obtained nanoparticles in water followed a decreasing trend as 
the Tt-UCST increased (Fig. 3c). This can be attributed to the different hydration state of the 
copolymers depending on the temperature of the solution. All formulations were prepared at room 
temperature (circa 23 °C) and measured at 20 °C. For the copolymer having a Tt-UCST at 30 °C (P1), 
the DLS measurements were not appropriate as the obtained suspension was on the micron size 
range. While Tt-UCST of P1 was measured at 30 °C, the onset temperature is lower, close to 20 °C. The 
copolymer chains were thus hydrated and the nanoparticles swollen. As the Tt-UCST increased, so did 
the hydrophobicity of the copolymer, which in turn hindered the interactions between water 
molecules and the copolymer chains thus yielding more compact nanoparticles. The trend reached 
a lower point at 154 nm with 0.09 as a PdI for P8. 
Formulation of the thermoresponsive copolymers into nanoparticles in different aqueous media 
modified their physico-chemical properties. For instance, P6 led to nanoparticles with a greater 
average diameter in PBS than in water (Supplementary Information Fig. S5a), revealing a higher 
hydration state in such a medium. This result is well-correlated with the UCST behavior as the 
temperature onset for thermoresponsiveness was lower in PBS than in water. DLS measurements 
were also carried out at 37 °C for P2 nanoparticles formulated in water (Supplementary 
Information Fig. S5b). The swelling behavior was observed here once again, as the copolymer 
chains preferentially interacted with water molecules at higher temperature. This result was 
indicative of the solubilization mechanism of the nanoparticles as they appeared to swell to bigger 
sizes before eventually becoming fully soluble at a temperature higher than the Tt-UCST.  
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Figure 4: TEM images of P2 unloaded nanoparticles (left), P7 unloaded nanoparticles (right). 
As for the morphology of the different nanoparticles, TEM images suggested a significant influence 
of the copolymer’s Tt-UCST (Fig. 4). Indeed, for a high Tt-UCST (P7), the nano-objects appeared to be 
well-defined spheres whereas at a lower Tt-UCST (P2), the suspension was not homogeneous, and the 
nano-objects seemed to be fused together in ill-defined shapes. A compromise was made in terms of 
selection of the polymer for further drug encapsulation studies, as P2 offered the best choice in 
terms of Tt-UCST but formed particles larger than 300 nm. The subsequent studies were carried out 
with P2. 
3.3. Impact of doxorubicin loading on the nanoparticle properties 
Doxorubicin hydrochloride is a water-soluble anticancer drug widely used to treat a variety of 
cancers. Here, Dox was rendered hydrophobic by letting it react with triethylamine (weak 
base).[23,27] It will therefore be encapsulated in the P(AAm-co-AN) hydrophobic core of 
nanoparticles. We studied the impact of Dox loading on the physico-chemical properties of the 
nanoparticles. Note that nanoparticles were formulated in water, as formulation in PBS resulted in 
precipitation of Dox. 
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Figure 5: Physico-chemical properties of Dox loaded NPs formulated with P2 at 4.5 mg.mL-1 
polymer concentration in water. (a) Drug loading content (DL) and (b) encapsulation efficiency 
(EE) as a function of initial mass of doxorubicin. (c) Dz and (d) ζ-potential values as a function of 
encapsulated Dox (n ≥ 2). 
The drug loading of Dox showed a linear increase as a function of the initial amount of Dox up to 3.3 
mg of initial Dox where the DL value stabilized at around 4 wt.% (Fig. 5a). Interestingly, this 
maximum DL  value was in agreement with other studies where Dox was encapsulated in regular 
non-thermoresponsive polymer nanoparticles.[37,38] Above this maximum value, the copolymer 
matrix was saturated with Dox and was not able to incorporate more drug. This effect was clearly 
supported by looking at the encapsulation efficiency, which increased from 30 to 50 wt.% as the 
initial Dox mass increased, and then decreased after saturation of the copolymer matrix (Fig. 5b). 
Encapsulation of Dox also modified the size and surface charge properties of the nanoparticles as 
shown in Fig. 5c and 5d. The size followed a decreasing trend as encapsulated Dox increased, and 
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the surface zeta-potential (ζ) became significantly more negative in the presence of Dox compared 
to unloaded nanoparticles, likely because of the deprotonated state of Dox. The change in surface 
charge was also indicative of the encapsulation of the drug in the polymer matrix. As for the size 
decrease of the nanoparticles, it may be due to a preferential interaction between Dox and the 
copolymer chains, where Dox acted as a hydrophobic nucleus facilitating the formation of more 
compact and dense nanoparticles. 
 
 
Figure 6: Doxorubicin encapsulation impact on Tt-UCST of formulated nanoparticles from P2 at 4.5 
mg.mL-1 in water. (a) Heating transmittance curves with various amounts of encapsulated Dox. (b) 
Heating and cooling Tt-UCST values depending on the amount of encapsulated Dox. Cooling curves in 
Supplementary Information Fig. S8. (c) Transmittance curves of unloaded P2 nanoparticles at 4.5 
mg.mL-1 (red), 4x dilution (green) and 10x dilution (pink) in water. (c) Transmittance curves of 
Dox-loaded P2 nanoparticles at 4.5 mg.mL-1 (red), 4x dilution (purple) and 10x dilution (brown) in 
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water. Lines represent heating transmittance curves; dotted lines represent cooling transmittance 
curves. 
 
Upon increasing the amount of encapsulated Dox in the nanoparticles, the Tt-UCST increased both for 
the heating curve (Fig. 6a) and the cooling curve (Fig. 6b). The maximum transmittance value of the 
nanoparticles containing Dox did not reach 100% due to the presence of Dox that absorbed part of 
the incoming light even at a high wavelength (600 nm). The maximum transmittance value 
decreased with increasing the Dox content. The change in Tt-UCST for the heating and cooling curves 
showed an increase of the hysteresis of the system with increasing the encapsulated Dox content 
(Fig. 6b). In agreement with our hypothesis, the hysteresis might be due to the strong interaction 
between Dox and the copolymer chains, resulting in more energy needed to disrupt the Dox-
copolymer interactions and fully solubilize the copolymer chains in water. The cooling Tt-UCST 
values, while higher than that obtained for unloaded nanoparticles, remained constant for the 
different amounts of encapsulated Dox. This observation can be attributed to the drug release: once 
Dox was freed from the nanoparticles, the Tt-UCST came back to a value closer to that of the unloaded 
nanoparticles. 
Thermoresponsive copolymers exhibited a phase diagram in aqueous medium that displayed a 
concentration-dependent cloud point. This aspect must be elucidated to verify if the 
thermoresponsive properties of the nanoparticle formulation at 4.5 mg.mL-1 of copolymer 
remained similar upon dilution, which is an important feature for the applicability.Dilution 
decreased the Tt-UCST of the suspensions even in the presence of Dox (Fig. 6c and d). While the 
thermoresponsiveness was retained, a shift of the Tt-UCST towards lower values was observed; from 
47 °C down to 40 °C in the case of unloaded nanoparticles (Fig. 6c). Not only did the Tt-UCST decrease 
but also the onset temperature; from 30 °C to below 20 °C. For Dox-loaded nanoparticles, this 
phenomenon was still observed (Fig. 6d). For the cooling Tt-UCST values, they were equal to 51, 42 
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and 37 °C for undiluted, 4 times diluted and 10 times diluted suspensions, respectively. This change 
of Tt-UCST upon dilution raised questions regarding the applicability of this system for clinical use. 
Indeed, once administered to the patient intravenously, the formulation undergoes an important 
dilution, from a 500 mL perfusion bag to a 5-liter blood volume. This issue may be tackled by 
heating the tumor at mild-hyperthermia prior to the administration of the formulation, to minimize 
the chance of uncontrolled drug release. 
Upon Dox loading, the overall shape of the nanoparticles visible by TEM did not change conversely 
to the size which appeared to be smaller (Supplementary Information, Fig. S6), which is in 
agreement with DLS measurements. Traditional polymer nanoparticles made from amphiphilic 
diblock copolymers, such as PLA-b-PEG, exhibit a well-defined spherical shape. Solubility of P(AAm-
co-AN)-b-POEGMA in water is temperature- and concentration-dependent unlike PLA-b-PEG. Thus, 
our hypothesis is that in observation conditions, as nanoparticles are diluted to allow observation, 
some copolymer chains were solubilized and allowed merging of different nanoparticles to form ill-
defined objects. 
3.4. Cell culture 
The aim of the cell culture studies was to show an enhanced activity of Dox encapsulated in 
nanoparticles under mild hyperthermia conditions. OVCAR-3 cells were chosen as they are Dox-
sensitive and represent a good cancer model for localized hyperthermia.[39,40] The mitochondrial 
activity results showed that unloaded nanoparticles were not toxic up to 500 µg.mL-1, whereas 60 
% of mitochondrial activity was retained at 1 mg.mL-1 (Fig. 7a). This result was encouraging as it 
showed that the thermoresponsive copolymer used is rather well-tolerated making it a good 
candidate for drug delivery applications.  
Mild hyperthermia was applied for 30 min, at 6 h or 24 h post-treatment. The trend showed that 
cytotoxicity was greater when hyperthermia was applied 24 h post-treatment rather than 6 h post-
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treatment (Fig. 7). This trend was verified in the case of free Dox and for Dox-loaded nanoparticles 
although not statistically significant. IC50 for free Dox was at 0.8 mM, whereas the IC50 for Dox-
loaded nanoparticles was at 7.2 mM (Fig. 7d). The increase of the IC50 was due to the encapsulation 
of the drug in the nanoparticles, where it is rendered less accessible to the cells. Dox induced its 
anticancer activity inside the cells’ nucleus where it intercalates between complementary DNA 
strands, inhibiting the progression of topoisomerase II and further blocking proper transcription 
and replication.[41] This mechanism of action thus requires Dox to reach the cells’ nucleus and not 
only reside in the cytosol for it to exert its anticancer activity. In the results shown here, the 5-fold 
difference between free Dox and encapsulated Dox is significant and might be due to the strong 
affinity between the copolymer and Dox mentioned earlier in the manuscript. Indeed, if Dox has a 
strong affinity with the copolymer, it may not readily be released from the nanoparticles and reach 
the cell’s nucleus, as it might be retained by the copolymer, which has a large molar mass not 
allowing proper diffusion to the cell’s nucleus. However, upon hyperthermia, the polymer chains 
should be solubilized, allowing Dox to freely diffuse away from the copolymer. As our results under 
hyperthermia showed that Tt-UCST of Dox-loaded nanoparticles decreased upon dilution, we 
expected to see a difference between unheated and heated nanoparticles. While there was a visible 
trend, we were not able to obtain the same activity, i.e. same IC50, as the free Dox when treating 
with Dox-loaded nanoparticles with hyperthermia.  
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Figure 7: Mitochondrial activity of OVCAR-3 cells in the presence of unloaded P2 nanoparticles (a), 
free Dox (b), or Dox-loaded P2 nanoparticles (c) ± hyperthermia (43 °C). For unloaded 
nanoparticles, dashed line indicates 80% mitochondrial activity, for others dashed line indicates the 
IC50 (d).  
Several aspects of the system can be improved to address some of the limitations presented in this 
study. Regarding the dilution affecting the UCST, a possible solution would be to add a hydrophobic 
block to the polymer that would act as a solid foundation upon which the nanoparticles could be 
built. This would force the thermoresponsive copolymer chains to remain close to each other at any 
dilution. On the contrary, this solution may also force the drug to be primarily encapsulated in the 
hydrophobic polymer chains, thus having potentially less drug release upon heating. Nevertheless, 
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this methodology is already extensively used for LCST-type drug delivery systems and would be 
interesting to test for UCST-type drug delivery systems. The nature of the encapsulated anticancer 
drug can also be changed to select a molecule whose anticancer mechanism takes place inside the 
cell’s cytosol as opposed to its nucleus. For instance, taxane derivatives such as paclitaxel are good 
candidates as they disrupt the microtubules’ stability in the cytosol. In terms of physico-chemistry, 
these drugs are already hydrophobic, simplifying the preparation of the drug-loaded nanoparticles. 
 
4. Conclusion 
The aim of this study was to formulate thermoresponsive nanoparticles from P(AAm-co-AN), a 
hydrogen bonding-based UCST copolymer building block. We successfully synthesized UCST-type 
P(AAm-co-AN)-b-POEGMA diblock copolymer by a two-step RAFT polymerization and successfully 
tuned the thermoresponsiveness by varying the amount of AN in the copolymer. The copolymer 
was formulated into nanoparticles by the nanoprecipitation technique into stable nanoparticles of 
different sizes and dispersity governed by the Tt-UCST of the copolymer: the higher the Tt-UCST, the 
smaller the size. Encapsulation of Dox was achieved and modified the properties of the 
nanoparticles in a way never reported before. Surprisingly, the higher the amount of encapsulated 
Dox, the higher the Tt-UCST of the nanoparticles. In vitro, unloaded nanoparticles were not toxic up to 
500 µg.mL-1. However, the effect of hyperthermia on cell viability was not significant probably due 
to the modification of Tt-UCST of the nanoparticles upon dilution. The system can still be improved by 
changing the encapsulated drug or adding a hydrophobic polymer block to yield a better-defined 
suspension less sensitive to dilution effects. Taken together, these results highlighted the crucial 
role of the drug encapsulation and dilution on the expected beneficial effect of the 
thermoresponsiveness. Therefore, it seems important to carefully study those parameters for any 
kind of thermosensitive nanoscale drug delivery systems. 
25 
 
5. Acknowledgements 
Authors acknowledge the support of la Ligue contre le Cancer for Alexandre Bordat’s Ph.D. 
fellowship, Cancéropôle IDF Emergence and Fondation ARC for funding. The present work has 
benefited also from the core facilities of Imagerie-Gif, (http://www.i2bc.paris-saclay.fr), member of 
IBiSA (http://www.ibisa.net), supported by “France-BioImaging” (ANR-10-INBS-04-01), and the 
Labex “Saclay Plant Science” (ANR-11-IDEX-0003-02). Institut Galien Paris-Sud is a member of the 
Laboratory of Excellence LERMIT supported by a grant from ANR (ANR-10-LABX-33). Authors 
would like to acknowledge the precious help of S. Denis for cell culture and C. Dejean for NMR. 
Supplementary Information: 
Polymer reaction mixture compositions are presented as well as NMR spectra, SEC chromatograms, 
some transmittance curves, IR spectrum and IR calibration curve. 
 
6. References 
[1] D.E. Owens, N.A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric 
nanoparticles, Int. J. Pharm. 307 (2006) 93–102. doi:10.1016/J.IJPHARM.2005.10.010. 
[2] M.E.R. O’Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. Kieback, G., P. 
Tomczak, S. Ackland, P., F. Orlandi, L. Mellars, L. Alland, C. Tendler, Reduced cardiotoxicity and 
comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) 
versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann. Oncol. 
15 (2004) 440–449. doi:10.1093/annonc/mdh097. 
[3] S. Mura, J. Nicolas, P. Couvreur, Stimuli-responsive nanocarriers for drug delivery, Nat. Mater. 12 
(2013) 991–1003. doi:10.1038/nmat3776. 
[4] T. Boissenot, A. Bordat, E. Fattal, N. Tsapis, Ultrasound-triggered drug delivery for cancer 
treatment using drug delivery systems: From theoretical considerations to practical applications, 
J. Control. Release. 241 (2016) 144–163. doi:10.1016/j.jconrel.2016.09.026. 
[5] D.E. Kruse, Chun-Yen Lai, D.N. Stephens, P. Sutcliffe, E.E. Paoli, S.H. Barnes, K.W. Ferrara, Spatial 
and Temporal-Controlled Tissue Heating on a Modified Clinical Ultrasound Scanner for 
Generating Mild Hyperthermia in Tumors, IEEE Trans. Biomed. Eng. 57 (2010) 155–166. 
doi:10.1109/TBME.2009.2029703. 
26 
 
[6] J.E. Johnson, P.F. Maccarini, D. Neuman, P.R. Stauffer, Automatic Temperature Controller for 
Multielement Array Hyperthermia Systems, IEEE Trans. Biomed. Eng. 53 (2006) 1006–1015. 
doi:10.1109/TBME.2006.873559. 
[7] Y. Nagata, M. Hiraoka, Y. Nishimura, S. Masunaga, M. Mitumori, Y. Okuno, M. Fujishiro, S. 
Kanamori, N. Horii, K. Akuta, K. Sasai, M. Abe, Y. Fukuda, Clinical results of radiofrequency 
hyperthermia for malignant liver tumors, Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 359–65. 
doi:10.1016/S0360-3016(96)00625-6. 
[8] G. Hoffmann, Principles and working mechanisms of water-filtered infrared-A (wIRA) in relation 
to wound healing., GMS Krankenhhyg. Interdiszip. 2 (2007). 
[9] G. Kong, R.D. Braun, M.W. Dewhirst, Hyperthermia Enables Tumor-specific Nanoparticle Delivery: 
Effect of Particle Size, Cancer Res. 60 (2000) 4440 LP – 4445. 
[10] G. Kong, R.D. Braun, M.W. Dewhirst, Characterization of the Effect of Hyperthermia on 
Nanoparticle Extravasation from Tumor Vasculature, Cancer Res. 61 (2001) 3027 LP – 3032. 
[11] S.K. Calderwood, J.R. Theriault, J. Gong, How is the immune response affected by hyperthermia 
and heat shock proteins?, Int. J. Hyperth. 21 (2005) 713–716. doi:10.1080/02656730500340794. 
[12] B. Hildebrandt, P. Wust, O. Ahlers, A. Dieing, G. Sreenivasa, T. Kerner, R. Felix, H. Riess, The 
cellular and molecular basis of hyperthermia, Crit. Rev. Oncol. Hematol. 43 (2002) 33–56. 
doi:10.1016/S1040-8428(01)00179-2. 
[13] M. Dunne, K. Hynynen, C. Allen, Thermosensitive nanomedicines could revolutionize thermal 
therapy in oncology, Nano Today. 16 (2017) 9–13. doi:10.1016/j.nantod.2017.08.001. 
[14] T. Ta, T.M. Porter, Thermosensitive liposomes for localized delivery and triggered release of 
chemotherapy, J. Control. Release. 169 (2013) 112–125. doi:10.1016/j.jconrel.2013.03.036. 
[15] M.C. Sandström, L.M. Ickenstein, L.D. Mayer, K. Edwards, Effects of lipid segregation and lysolipid 
dissociation on drug release from thermosensitive liposomes, J. Control. Release. 107 (2005) 
131–142. doi:10.1016/J.JCONREL.2005.06.001. 
[16] B. Banno, L.M. Ickenstein, G.N.C. Chiu, M.B. Bally, J. Thewalt, E. Brief, E.K. Wasan, The functional 
roles of poly(ethylene glycol)‐lipid and lysolipid in the drug retention and release from 
lysolipid‐containing thermosensitive liposomes in vitro and in vivo, J. Pharm. Sci. 99 (2010) 2295–
2308. doi:10.1002/JPS.21988. 
[17] S. Cammas, K. Suzuki, C. Sone, Y. Sakurai, K. Kataoka, T. Okano, Thermo-responsive polymer 
nanoparticles with a core-shell micelle structure as site-specific drug carriers, J. Control. Release. 
48 (1997) 157–164. doi:10.1016/S0168-3659(97)00040-0. 
[18] M. Karimi, P. Sahandi Zangabad, A. Ghasemi, M. Amiri, M. Bahrami, H. Malekzad, H. 
Ghahramanzadeh Asl, Z. Mahdieh, M. Bozorgomid, A. Ghasemi, M.R. Rahmani Taji Boyuk, M.R. 
Hamblin, Temperature-Responsive Smart Nanocarriers for Delivery of Therapeutic Agents: 
Applications and Recent Advances, ACS Appl. Mater. Interfaces. 8 (2016) 21107–21133. 
doi:10.1021/acsami.6b00371. 
[19] J. Seuring, S. Agarwal, First Example of a Universal and Cost-Effective Approach : Polymers with 
Tunable Upper Critical Solution Temperature in Water and Electrolyte Solution, Macromolecules. 
45 (2012) 3910–3918. 
27 
 
[20] F. Käfer, F. Liu, U. Stahlschmidt, V. Jérôme, R. Freitag, M. Karg, S. Agarwal, LCST and UCST in One: 
Double Thermoresponsive Behavior of Block Copolymers of Poly(ethylene glycol) and 
Poly(acrylamide-co-acrylonitrile), Langmuir. 31 (2015) 8940–8946. 
doi:10.1021/acs.langmuir.5b02006. 
[21] L. Hou, P. Wu, Understanding the UCST-type transition of P(AAm-co-AN) in H 2 O and D 2 O: 
dramatic effects of solvent isotopes, Soft Matter. 11 (2015) 7059–7065. 
doi:10.1039/C5SM01745A. 
[22] H. Zhang, X. Tong, Y. Zhao, Diverse Thermoresponsive Behaviors of Uncharged UCST Block 
Copolymer Micelles in Physiological Medium, Langmuir. 30 (2014) 11433–11441. 
doi:10.1021/la5026334. 
[23] G. Huang, H. Li, S.T. Feng, X. Li, G. Tong, J. Liu, C. Quan, Q. Jiang, C. Zhang, Z. Li, Self-assembled 
UCST-type micelles as potential drug carriers for cancer therapeutics, Macromol. Chem. Phys. 
216 (2015) 1014–1023. doi:10.1002/macp.201400546. 
[24] A. Asadujjaman, A. Bertin, A. Schönhals, Dielectric analysis of the upper critical solution 
temperature behaviour of a poly(acrylamide-co-acrylonitrile) copolymer system in water, Soft 
Matter. 13 (2017) 2384–2393. doi:10.1039/C6SM02684B. 
[25] A. Asadujjaman, B. Kent, A. Bertin, Phase transition and aggregation behaviour of an UCST-type 
copolymer poly(acrylamide-co-acrylonitrile) in water: effect of acrylonitrile content, 
concentration in solution, copolymer chain length and presence of electrolyte, Soft Matter. 13 
(2017) 658–669. doi:10.1039/C6SM02262F. 
[26] J. Yang, S. Zhai, H. Qin, H. Yan, D. Xing, X. Hu, NIR-controlled morphology transformation and 
pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for 
photoacoustic imaging-guided photothermal-chemotherapy, Biomaterials. 176 (2018) 1–12. 
doi:10.1016/J.BIOMATERIALS.2018.05.033. 
[27] W. Li, L. Huang, X. Ying, Y. Jian, Y. Hong, F. Hu, Y. Du, Antitumor Drug Delivery Modulated by A 
Polymeric Micelle with an Upper Critical Solution Temperature, Angew. Chemie Int. Ed. 54 (2015) 
3126–3131. doi:10.1002/anie.201411524. 
[28] B.Y.K. Chong, T.P.T. Le, G. Moad, E. Rizzardo, S.H. Thang, More versatile route to block 
copolymers and other polymers of complex architecture by living radical polymerization: the 
RAFT process, Macromolecules. 32 (1999) 2071–2074. doi:10.1021/ma981472p. 
[29] G. Moad, J. Chiefari, (Bill) Y?K Chong, J. Krstina, R.T. Mayadunne, A. Postma, E. Rizzardo, S.H. 
Thang, Living free radical polymerization with reversible addition - fragmentation chain transfer 
(the life of RAFT), Polym. Int. 49 (2000) 993–1001. doi:10.1002/1097-
0126(200009)49:9<993::AID-PI506>3.0.CO;2-6. 
[30] C. Tang, T. Kowalewski, K. Matyjaszewski, RAFT polymerization of acrylonitrile and preparation of 
block copolymers using 2-cyanoethyl dithiobenzoate as the transfer agent, Macromolecules. 36 
(2003) 8587–8589. doi:10.1021/ma034942a. 
[31] D.B. Thomas, A.J. Convertine, L.J. Myrick, C.W. Scales, A.E. Smith, A.B. Lowe, Y.A. Vasilieva, N. 
Ayres, C.L. McCormick, Kinetics and molecular weight control of the polymerization of acrylamide 
via RAFT, Macromolecules. 37 (2004) 8941–8950. doi:10.1021/ma048199d. 
[32] H. Otsuka, Y. Nagasaki, K. Kataoka, PEGylated nanoparticles for biological and pharmaceutical 
28 
 
applications, Adv. Drug Deliv. Rev. 64 (2012) 246–255. doi:10.1016/J.ADDR.2012.09.022. 
[33] F.M. Veronese, P. Caliceti, O. Schiavon, Branched and linear poly(ethylene glycol): Influence of 
the polymer structure on enzymological, pharmacokinetic, and immunological properties of 
protein conjugates, J. Bioact. Compat. Polym. 12 (1997) 196–207. 
doi:10.1177/088391159701200303. 
[34] J.-F. Lutz, Polymerization of oligo(ethylene glycol) (meth)acrylates: Toward new generations of 
smart biocompatible materials, J. Polym. Sci. Part A Polym. Chem. 46 (2008) 3459–3470. 
doi:10.1002/pola.22706. 
[35] J. Seuring, S. Agarwal, Polymers with upper critical solution temperature in aqueous solution, 
Macromol. Rapid Commun. 33 (2012) 1898–1920. doi:10.1002/marc.201200433. 
[36] H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, S. Benita, Nanocapsule formation by 
interfacial polymer deposition following solvent displacement, Int. J. Pharm. 55 (1989) R1–R4. 
doi:10.1016/0378-5173(89)90281-0. 
[37] T. Betancourt, B. Brown, L. Brannon-Peppas, Doxorubicin-loaded PLGA nanoparticles by 
nanoprecipitation: preparation, characterization and in vitro evaluation, Nanomedicine. 2 (2007) 
219–232. doi:10.2217/17435889.2.2.219. 
[38] J. Park, P.M. Fong, J. Lu, K.S. Russell, C.J. Booth, W.M. Saltzman, T.M. Fahmy, PEGylated PLGA 
nanoparticles for the improved delivery of doxorubicin, Nanomedicine Nanotechnology, Biol. 
Med. 5 (2009) 410–418. doi:10.1016/j.nano.2009.02.002. 
[39] S.-W. Wang, X.-Y. He, M.-Z. Li, High-intensity focused ultrasound compared with irradiation for 
ovarian castration in premenopausal females with hormone receptor-positive breast cancer after 
radical mastectomy., Oncol. Lett. 4 (2012) 1087–1091. doi:10.3892/ol.2012.860. 
[40] H. He, T. Yu, Y. Zhang, The Interaction between a Drug and Ultrasound in Sonochemotherapy 
against Ovarian Cancers, Ultraschall Der Medizin - Eur. J. Ultrasound. 33 (2010) 275–282. 
doi:10.1055/s-0029-1245876. 
[41] A. Bodley, L.F. Liu, M. Israel, R. Seshadri, Y. Koseki, F.C. Giuliani, S. Kirschenbaum, R. Silber, M. 
Potmesil, DNA Topoisomerase II-mediated Interaction of Doxorubicin and Daunorubicin 
Congeners with DNA, Cancer Res. 49 (1989) 5969–5978. 
 
 
